Chemodenervation for the Treatment of Facial Dystonia

To review the medical literature on the outcomes and complications of various Food and Drug Administration-approved botulinum toxins for benign essential blepharospasm (BEB) and hemifacial spasm (HFS).

http://www.aaojournal.org/article/S0161-6420(18)30687-0/fulltext?rss=yes

Source: Ophthalmology - April 10, 2018 Category: Opthalmology Authors: Jurij R. Bilyk, Michael T. Yen, Elizabeth A. Bradley, Edward J. Wladis, Louise A. Mawn Tags: Ophthalmic Technology Assessment Source Type: research

More News: Dystonia | Food and Drug Administration (FDA) | Opthalmology